Cargando…
A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity
BACKGROUND: Relatively poor penetration and retention in tumor tissue has been documented for large molecule drugs including therapeutic antibodies and recombinant immunoglobulin constant region (Fc)-fusion proteins due to their large size, positive charge, and strong target binding affinity. Theref...
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466810/ https://www.ncbi.nlm.nih.gov/pubmed/25881012 http://dx.doi.org/10.1186/s12885-015-1140-1 |